Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up

Br J Haematol. 2013 Dec;163(5):674-6. doi: 10.1111/bjh.12532. Epub 2013 Aug 19.
No abstract available

Keywords: BCR-ABL1; chronic myeloid leukaemia; stem cells; therapy; trials.

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides / administration & dosage*
  • Benzamides / adverse effects
  • Benzamides / therapeutic use
  • Cell Cycle / drug effects
  • Dasatinib
  • Drug Substitution
  • Drug Synergism
  • Follow-Up Studies
  • Fusion Proteins, bcr-abl / blood
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Piperazines / administration & dosage*
  • Piperazines / adverse effects
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Pulse Therapy, Drug
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use
  • Thiazoles / therapeutic use
  • Treatment Outcome

Substances

  • BCR-ABL1 fusion protein, human
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Granulocyte Colony-Stimulating Factor
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • nilotinib
  • Dasatinib